Lyell Immunopharma (NASDAQ:LYEL) Given “Market Outperform” Rating at Citizens Jmp

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “market outperform” rating reaffirmed by stock analysts at Citizens Jmp in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $34.00 price objective on the stock. Citizens Jmp’s target price would suggest a potential upside of 151.57% from the stock’s current price.

Several other equities analysts have also commented on the stock. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the company an “outperform” rating in a report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Needham & Company LLC restated a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a research report on Monday. Finally, Zacks Research raised Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Lyell Immunopharma has a consensus rating of “Moderate Buy” and an average price target of $43.00.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL traded up $0.02 during midday trading on Monday, reaching $13.52. 6,242 shares of the company’s stock were exchanged, compared to its average volume of 97,052. The stock has a market cap of $315.36 million, a price-to-earnings ratio of -0.98 and a beta of -0.09. Lyell Immunopharma has a fifty-two week low of $8.46 and a fifty-two week high of $45.00. The firm’s 50 day simple moving average is $19.17 and its two-hundred day simple moving average is $23.26.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, meeting analysts’ consensus estimates of ($1.10). The company had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. Equities research analysts predict that Lyell Immunopharma will post -7.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. ARCH Venture Management LLC increased its stake in Lyell Immunopharma by 51.5% during the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after buying an additional 938,438 shares during the period. GSK plc purchased a new position in Lyell Immunopharma in the 4th quarter valued at approximately $46,560,000. MWG Caph Ltd acquired a new position in shares of Lyell Immunopharma in the fourth quarter worth $31,030,000. Vanguard Group Inc. grew its stake in shares of Lyell Immunopharma by 76.0% in the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock worth $12,651,000 after acquiring an additional 336,378 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after acquiring an additional 443,614 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.